Bristol Myers Squibb (BMY) Cash & Equivalents (2009 - 2026)
Bristol Myers Squibb (BMY) reported Cash & Equivalents of $9.6 billion for Q1 2026, down 11.96% year-over-year from $10.9 billion in Q1 2025, and down 6.22% on a QoQ basis from $10.2 billion in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of Cash & Equivalents data on file, last reported at $9.6 billion in Q1 2026.
- Quarterly Cash & Equivalents fell 11.96% year-over-year to $9.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 billion (down 11.96% YoY) and the FY2025 annual result came in at $10.2 billion, down 1.32% from the prior year.
- Cash & Equivalents retreated to $9.6 billion in Q1 2026 per BMY's latest filing, from $10.2 billion in the prior quarter.
- Across five years, Cash & Equivalents topped out at $15.7 billion in Q3 2025 and bottomed at $6.3 billion in Q2 2024.
- The 5-year median for Cash & Equivalents is $9.6 billion (2026), against an average of $10.0 billion.
- The widest annual swing landed in 2022, when Cash & Equivalents plunged 42.88%; it then surged 100.21% in 2025.
- Tracing BMY's Cash & Equivalents over 5 years: stood at $9.1 billion in 2022, then grew by 25.66% to $11.5 billion in 2023, then slipped by 9.75% to $10.3 billion in 2024, then retreated by 1.32% to $10.2 billion in 2025, then slipped by 6.22% to $9.6 billion in 2026.
- Per Business Quant, the three latest BMY Cash & Equivalents figures stand at $9.6 billion (Q1 2026), $10.2 billion (Q4 2025), and $15.7 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 21.69 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 9.57 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 4.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.57 Bn |
| Dec 31, 2025 | 10.21 Bn |
| Sep 30, 2025 | 15.73 Bn |
| Jun 30, 2025 | 12.60 Bn |
| Mar 31, 2025 | 10.88 Bn |
| Dec 31, 2024 | 10.35 Bn |
| Sep 30, 2024 | 7.89 Bn |
| Jun 30, 2024 | 6.29 Bn |
| Mar 31, 2024 | 9.33 Bn |
| Dec 31, 2023 | 11.46 Bn |
| Sep 30, 2023 | 7.51 Bn |
| Jun 30, 2023 | 8.37 Bn |
| Mar 31, 2023 | 9.00 Bn |
| Dec 31, 2022 | 9.12 Bn |
| Sep 30, 2022 | 7.73 Bn |
| Jun 30, 2022 | 10.75 Bn |
| Mar 31, 2022 | 12.37 Bn |
| Dec 31, 2021 | 13.98 Bn |
| Sep 30, 2021 | 13.54 Bn |
| Jun 30, 2021 | 11.02 Bn |
| Mar 31, 2021 | 10.98 Bn |
| Dec 31, 2020 | 14.55 Bn |
| Sep 30, 2020 | 19.44 Bn |
| Jun 30, 2020 | 19.93 Bn |
| Mar 31, 2020 | 15.82 Bn |
| Dec 31, 2019 | 12.35 Bn |
| Sep 30, 2019 | 30.49 Bn |
| Jun 30, 2019 | 28.40 Bn |
| Mar 31, 2019 | 7.34 Bn |
| Dec 31, 2018 | 6.91 Bn |
| Sep 30, 2018 | 5.41 Bn |
| Jun 30, 2018 | 5.00 Bn |
| Mar 31, 2018 | 5.34 Bn |
| Dec 31, 2017 | 5.42 Bn |
| Sep 30, 2017 | 4.64 Bn |
| Jun 30, 2017 | 3.47 Bn |
| Mar 31, 2017 | 3.91 Bn |
| Dec 31, 2016 | 4.24 Bn |
| Sep 30, 2016 | 3.43 Bn |
| Jun 30, 2016 | 2.93 Bn |
| Mar 31, 2016 | 2.64 Bn |
| Dec 31, 2015 | 2.39 Bn |
| Sep 30, 2015 | 3.98 Bn |
| Jun 30, 2015 | 4.20 Bn |
| Mar 31, 2015 | 6.29 Bn |
| Dec 31, 2014 | 5.57 Bn |
| Sep 30, 2014 | 4.85 Bn |
| Jun 30, 2014 | 4.28 Bn |
| Mar 31, 2014 | 5.23 Bn |
| Dec 31, 2013 | 3.59 Bn |
| Sep 30, 2013 | 1.77 Bn |
| Jun 30, 2013 | 1.82 Bn |
| Mar 31, 2013 | 1.36 Bn |
| Dec 31, 2012 | 1.66 Bn |
| Sep 30, 2012 | 1.50 Bn |
| Jun 30, 2012 | 2.80 Bn |
| Mar 31, 2012 | 2.31 Bn |
| Dec 31, 2011 | 5.78 Bn |
| Sep 30, 2011 | 4.47 Bn |
| Jun 30, 2011 | 3.67 Bn |
| Mar 31, 2011 | 3.41 Bn |
| Dec 31, 2010 | 5.03 Bn |
| Sep 30, 2010 | 7.58 Bn |
| Jun 30, 2010 | 5.92 Bn |
| Mar 31, 2010 | 5.14 Bn |
| Dec 31, 2009 | 7.68 Bn |
| Sep 30, 2009 | 6.37 Bn |
| Jun 30, 2009 | 7.51 Bn |